{"nctId":"NCT00795704","briefTitle":"Impact of Mulberry Leaf on Type 2 Diabetes","startDateStruct":{"date":"2008-04"},"conditions":["Type 2 Diabetes"],"count":24,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Mulberry Leaf Extract","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Mulberry Leaf Extract"]}],"interventions":[{"name":"Mulberry Leaf Extract","otherNames":["Mulberry","Morus indica L.","Morus alba"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes\n* No diabetes medication adjustments for at least 2 months\n* Stable hemoglobin A1C \\[Between 7.0% to 8.0% (inclusive) and not varying by more than 10% since prior visit; If no A1C exists prior to the current visit and no medication adjustments are made, the current A1C may used as the baseline\\]\n\nExclusion Criteria:\n\n* On insulin\n* History of overt cardiovascular disease\n* History of missed appointments or non-compliance with medications\n* History of hepatic or renal insufficiency\n* History of hemoglobinopathies\n* Women of reproductive potential not on oral contraceptives\n* Pregnant/nursing women.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hemoglobin A1C","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.39","spread":"0.51"},{"groupId":"OG001","value":"-0.26","spread":"0.50"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Drug Reactions, Abnormal Metabolic Panel Levels, or Abnormal Liver Enzyme Levels","description":"Sodium (\\>150 mmol/L), Potassium (\\>5 mmol/L), Bicarbonate (\\>34 mmol/L), Chloride (\\>110 mmol/L), Serum Creatinine (\\>1.2 mg/dL), Blood Urea Nitrogen (24 mg/dL), Calcium (\\>11 mg/L), Alanine Aminotransferase (\\>3 times baseline), Aspartate Aminotransferase (\\>3 times baseline) were collected at baseline, 1 month, and 3 months. Self-Reported adverse drug reactions are also reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Self-Monitoring Blood Glucose (SMBG) Averages","description":"2-hour postprandial SMBG reported. A negative value indicates a decrease from baseline. A positive value indicates an increase from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.1","spread":"36.3"},{"groupId":"OG001","value":"3.6","spread":"13.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":12},"commonTop":["GI Upset","Infection","Allergy","Hyperparathyroidism"]}}}